Novo Nordisk's new obesity pill, amycretin, has shown promising results in early clinical trials, with participants losing up to 13% of their body weight in just 12 weeks, significantly outperforming placebo groups. The treatment may offer faster weight loss than Novo's popular Wegovy injection.

Forbes